ERBB2 and ovarian carcinoma: Additional indications include melanoma with BRAF 600E and V600K alterations, breast cancer with ERBB2 (HER2) amplification, colorectal cancer with KRAS wild-type (absence of mutations in codons 12 and 13, or exons two, three, and four) and NRAS wild-type, and ovarian cancer with BRCA1/2 alterations.